DXCM - DexCom, Inc.
| Previous close | 361.83 |
| Open | 367.48 |
| Bid | 378.31 x 1100 |
| Ask | 380.00 x 1100 |
| Day's range | 364.01 - 379.09 |
| 52-week range | 118.42 - 428.59 |
| Volume | 1,324,428 |
| Avg. volume | 1,905,876 |
| Market cap | 35.674B |
| Beta (5Y monthly) | 0.73 |
| PE ratio (TTM) | 237.78 |
| EPS (TTM) | 1.59 |
| Earnings date | 29 Jul 2020 - 03 Aug 2020 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 363.56 |
- Zacks
DexCom (DXCM) Up 4.1% Since Last Earnings Report: Can It Continue?
DexCom (DXCM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
Varian (VAR) Unveils New Features for Noona Software
This development, which is in response to the challenges brought on by the pandemic, is expected to boost Varian's (VAR) Oncology segment.
- Zacks
5 Health Care Stocks to Bet on as Coronavirus Woes Linger
The health care industry has been rallying so far this year on constant testing and COVID-19 vaccine trials.
- Zacks
Here's Why You Should Add Surmodics to Your Portfolio Now
Investor confidence is high in Surmodics (SRDX) stock, thanks to solid prospects.
- Bloomberg
Surging Diabetes Market Lifts Dexcom Into Top Spot in S&P 500
(Bloomberg) -- Dexcom Inc.’s recent entry into the S&P 500 gave the benchmark a new leader for the year, dethroning stocks like Newmont Corp. and Regeneron Pharmaceuticals Inc. that have seen share prices surge in the face of the coronavirus pandemic.The medical device company’s 85% rally this year is 30 percentage points ahead of the next four closest stocks in the S&P 500. While Dexcom rose to a fresh record last week after replacing Allergan Plc in the index, the debate for further gains is a hot one.Dexcom is among the few medtech companies that benefits from Covid-19. Its biggest Wall Street bull, Baird analyst Jeff Johnson, expects the stock to increase another 18% over the next 12 months. Other analysts including the team from Wells Fargo have cautioned that the current valuation matches its position in the fast-growing diabetes management market.Dexcom’s continuous glucose monitoring system, or CGM, allows diabetic patients to monitor their blood sugar levels day and night in place of fingersticks. The company’s G6 system is a small, wearable sensor and transmitter that sends a patient’s glucose number to their smartphone or watch every five minutes. The easy-to-use technology has served as a boon for sales with the company reporting 44% revenue growth in the first three months of the year.“It is an expensive stock, but you’re starting to see some real evidence that there are incremental revenue opportunities that aren’t in models that could emerge over the next few years,” Johnson said by telephone. He sees potential for more sales in both Type 1 and Type 2 diabetes due to CGM’s “high accuracy, improved convenience.”While the Covid-19 pandemic sent shockwaves through much of the medical technology landscape as elective surgeries were halted, Dexcom has seen continued demand for its products. The fact that diabetics have greater odds of complications related to coronavirus has “driven home the need to get even more diabetes patients on CGM because of the higher risk,” according to Johnson.The stock’s record-setting run has left many analyst price targets in the dust. Tuesday’s $404.57 close was higher than all but two 12-month price targets among analysts surveyed by Bloomberg. The average price target actually implies shares will lose 10% of their value a year from now.Wells Fargo analyst Larry Biegelsen, who started covering Dexcom with an equal weight rating just last week, thinks the next-generation G7 system could drive market share gains next year. The upgraded CGM system paired with international demand and use by patients in hospitals could be significant drivers of growth, Biegelsen wrote. But the near-term opportunities are already reflected in the stock price, he said.Smaller diabetes stocks have also captivated health specialists over recent years as investors look to cash in on the booming market. Insulet Corp., a $13 billion maker of the wearable and tubeless insulin delivery system OmniPod, has surged more than 580% in the past five years. And Tandem Diabetes Care Inc.’s insulin pump business has fueled its market value surge to $5 billion from less than $20 million three years ago.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
- Zacks
Here's Why You Should Retain Merit Medical (MMSI) for Now
Investor confidence is high in Merit Medical (MMSI) stock, thanks to solid prospects.
- Zacks
Allscripts Unit Inks Deal to Boost Veradigm AccelRx Platform
This deal is expected to bolster Allscripts' (MDRX) Clinical and Financial Solutions segment.
- Zacks
Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?
Is (DXCM) Outperforming Other Medical Stocks This Year?
- Motley Fool
DexCom and Domino’s Pizza Join the S&P 500. Should You Buy?
For years there has been chatter about the "S&P; phenomenon," which supposedly confers a bump in price to new additions to the index.
- Zacks
Nasdaq ETF (QQQ) Joins $100 Billion Club: 10 Stock Winners
Invesco QQQ (QQQ), which tracks the Nasdaq 100 Index, joined the $100 billion club of AUM last week.
- Zacks
ESG Stocks Remain Resilient to Virus Slump: 5 Top Picks
ESG stocks bear lesser financial risk due to their focus on environment, employees and supply chain. Investment in these companies can return well.
- Business Wire
DexCom Prices Offering of Upsized $1.05 Billion of 0.25% Convertible Senior Notes
DexCom Prices Offering of Upsized $1.05 Billion of 0.25% Convertible Senior Notes
- Motley Fool
Why DexCom Stock Rocketed Higher in April
What happened Medical device company DexCom (NASDAQ: DXCM) saw its shares gain a stately 31.5% during the month of April, according to data from S&P Global Market Intelligence. The company's shares burst higher last month for two inter-related reasons.
- Business Wire
DexCom Announces Proposed Offering of $850.0 Million of Convertible Senior Notes
DEXCOM ANNOUNCES PROPOSED OFFERING OF $850.0 MILLION OF CONVERTIBLE SENIOR NOTES
- Business Wire
DexCom, Inc. Announces Change of Location of Annual Meeting of Stockholders to Be Held May 21, 2020
DexCom, Inc. Announces Change of Location of Annual Meeting of Stockholders to Be Held May 21, 2020
- Motley Fool
Coronavirus Pandemic Propels User Growth for Livongo Health
Shares of Livongo Health (NASDAQ: LVGO), maker of remote patient-monitoring solutions, soared 12% to an all-time high Thursday after the company reported first-quarter results. Revenue grew 115% to $68.
- Zacks
Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year?
Is (DXCM) Outperforming Other Medical Stocks This Year?
- Motley Fool
3 "Non-Coronavirus Stocks" That Would Have Doubled Your Money Over the Last Year
Stocks of companies getting a direct tailwind from the COVID-19 pandemic aren't the only top performers in 2020 and over the last year.
- Zacks
DexCom (DXCM) Q1 Earnings and Revenues Surpass Estimates
DexCom's (DXCM) first-quarter earnings benefit from solid segmental performance.
- Motley Fool
How DexCom's Q1 Results Trounced Wall Street Expectations
The maker of continuous glucose monitoring (CGM) systems announced its first-quarter results after the market closed on Tuesday. Here are the highlights from DexCom's Q1 update. DexCom announced first-quarter revenue of $405.1 million, an impressive 44% year-over-year jump.
- Motley Fool
DexCom (DXCM) Q1 2020 Earnings Call Transcript
DXCM earnings call for the period ending March 31, 2020.
- Zacks
DexCom (DXCM) Tops Q1 Earnings and Revenue Estimates
DexCom (DXCM) delivered earnings and revenue surprises of 340.00% and 14.01%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Dexcom Reports First Quarter 2020 Financial Results
Dexcom Reports First Quarter 2020 Financial Results
- Simply Wall St.
How Good Is DexCom, Inc. (NASDAQ:DXCM), When It Comes To ROE?
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
- Zacks
Why DexCom (DXCM) Might Surprise This Earnings Season
DexCom (DXCM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
